---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-007542"
form_type: "8-K"
ticker: "AEMD"
cik: "0000882291"
company_name: "AETHLON MEDICAL INC"
filed_at: "2026-10-01T21:24:17+00:00"
generated_at: "2026-10-12T14:28:51.263046+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aethlon Medical stockholders approve charter amendments and 2020 Equity Incentive Plan increase

## Summary
- Stockholders approved increasing authorized common stock from 20,000,000 to 200,000,000 shares and authorizing 20,000,000 preferred shares, $0.001 par value.
- Stockholders approved adding 100,000 shares to the 2020 Equity Incentive Plan; the proposal received 204,289 votes for and 8,407 against.
- Stockholders approved issuing up to 1,126,602 common shares upon exercise of July 2026 Common Warrants and Placement Agent Warrants under Nasdaq Rule 5635(d).
- Annual Meeting held October 1, 2026; 399,752 of 711,136 shares (56.21%) represented by proxy or virtually, establishing a quorum.
- Five directors elected: Edward G. Broenniman, James B. Frakes, Nicolas Gikakis, Angela Rossetti, and Chetan S. Shah, MD.

## SEC filing metadata
- accession: 0001683168-26-007542
- form_type: 8-K
- ticker: AEMD
- cik: 0000882291
- company_name: AETHLON MEDICAL INC
- filed_at: 2026-10-01T21:24:17+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882291/000168316826007542/0001683168-26-007542-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882291/000168316826007542/aethlon_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-007542
- JSON: https://secwatch.observer/filing/0001683168-26-007542.json
- Plain text: https://secwatch.observer/filing/0001683168-26-007542.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.